EMERGENT BIOSOLUTIONS INC.

Drug pipeline (14)

Asset	Stage	Revenue	Trials	Status
ACAM2000	approved	—	0	—
ACCRETROPIN	approved	—	60	approved
ANTHRASIL	approved	—	0	—
BAT	approved	—	4	approved
BIORAB	approved	—	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (36)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05142306	phase1	completed	2021-12-07	2022-03-28	Emergent BioSolutions	A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
NCT04661839	phase1	completed	2020-12-24	2021-07-27	Emergent BioSolutions	A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
NCT01979406	phase1	completed	2013-11-01	2014-10-01	Emergent BioSolutions	A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
NCT01770743	phase2	completed	2013-01-01	2014-02-01	Emergent BioSolutions	A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
NCT03160339	phase1	terminated	2017-05-01	2017-11-27	Emergent BioSolutions	A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

FDA applications (13)

Application

Approved

Type

Applicant

Products

BLA 125761

2023-07-20

BLA

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC.

NDA 214460

2021-06-04

NDA

EMERGENT BIODEFENSE OPERATIONS LANSING LLC

NDA 214461

2021-06-04

NDA

EMERGENT BIODEFENSE OPERATIONS LANSING INC

BLA 761172

2020-12-21

BLA

EMERGENT BIODEFENSE OPERATIONS LANSING LLC

NDA 208411

2015-11-18

NDA

EMERGENT OPERATIONS IRELAND LTD